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A randomized, double-blind, cross-over study was conducted to assess the efficacy and safety of fluticasone 
propionate 1 mg twice daily administered via a pressurized metered ose inhaler (pMDI) containing the new non- 
chlorofluorocarbon (CFC) propellant (HFA 134a), or the established CFC propellants 11 and 12 in patients with 
severe asthma. The study comprised a 2-week run-in period followed by two 6-week treatment periods, with no 
washout period in between. One hundred and nineteen symptomatic adult patients with severe asthma, who were 
receiving inhaled beclomethasone 2-4 mg day-I or equivalent, were randomized to treatment. 
Patients were randomized to one of two sequence groups (sequence I: HFA 134a pMDI then CFC pMDI or 
sequence 2: CFC pMDI then HFA 134a pMDI). The sequence groups differed with respect to mean peak 
expiratory flow (PEF) at baseline; however, the magnitude of the increase in PEF from baseline during treatment 
was similar in the two sequence groups. Mean PEF at baseline was 3341min-I in sequence group 1 (HFA 
134a~CFC pMDI) and this increased to 357 1 min-tand 3661min -1 during treatment with the HFA 134a and 
CFC pMDI, respectively. In sequence group 2 (CFC--,HFA 134a pMDI) mean PEF at baseline was 297 1 min- i  
and this increased to 3361min - I and 328 I min - I  during treatment with the HFA 134a and CFC pMDI, 
respectively. 
Based on an overall analysis of the two treatment groups at week 6, equivalence was demonstrated; the mean 
treatment difference (HFA 134a-CFC pMDI) in morning PEF was 0 1 min-  i (90% confidence interval (CI), for 
difference between groups: - 7, 6 1 min-  t). There was a comparable improvement in secondary efficacy variables, 
including clinic lung function measurements, in the two treatment groups. The incidence and type of most adverse 
events were similar in the two treatment groups. There was no difference in the adjusted geometric mean morning 
serum cortisol evels after treatment with the HFA 134a and CFC pMDI. 
Therefore, the fluticasone propionate HFA 134a pMDI constitutes a suitable replacement for the established 
CFC pMDI at a microgram equivalent dose. 
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Introduction 
Fluticasone propionate is indicated for the prophylactic 
management of asthma of all severities (1-3). At a 
microgram equivalent dose, high-dose fluticasone 
Received 13 December 1999 and accepted in revised from 29 
February 2000. 
Correspondence should be addressed to: Prof, J. G. Ayres, 
Department of Respiratory Medicine, Birmingham Heartlands 
and Solihull NHS Trust (Teaching), Bordesley Green East, 
Birmingham B9 5SS, U.K. Fax: + 44(0) 121 772 0292. 
propionate (2 mg day - I)  is significantly more effective 
than budesonide (2mg day-l)  in terms of an improvement 
in lung function and symptom control in patients with 
severe asthma (4). Fluticasone propionate, incommon with 
all other inhaled corticosteroids, also has an oral steroid- 
sparing effect and has been reported to reduce or eliminate 
the need for oral corticosteroid therapy while improving 
lung function and quality of life in patients with severe 
asthma (5). 
With the need to phase out chlorofluorocarbons (CFC) 
as propellants in pressurized metered dose inhalers 
(pMDIs), there has been a need to find a safe replacement 
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propellant. As part of this transition, hydrofluoroalkane 
(HFA) propellants have been introduced. For fluticasone 
propionate, a 250 pg pressurized metered dose inhaler 
(pMDI) formulation has been developed as a microgram 
equivalent replacement for the traditional CFC pMDI. This 
study was designed to determine if a change in the pMDI 
propellant from CFC to HFA 134a would affect he efficacy 
and safety of fluticasone propionate 1000llg administered 
twice daily to patients with severe asthma. 
Methods  
STUDY DESIGN AND TREATMENT 
The study was of a multi-centre, randomized, ouble-blind, 
cross-over design with no washout period. During a 2-week 
run-in period, patients continued to use their usual asthma 
medication but replaced their short-acting ]/2-agonist with a 
salbutamol CFC pMDI (Ventolin TM) to be used on an as- 
required basis for symptomatic relief. At the end of the run- 
in period, patients discontinued their current inhaled 
corticosteriod therapy and were randomized to fluticasone 
propionate I mg twice daily administered via a CFC pMDI 
(containing propellants 11 and 12) or a non-CFC pMDI, 
containing the propellant HFA 134a, for the first 6 weeks of 
the study. At the end of this period patients immediately 
crossed over to the second 6-week treatment period and 
received the alternative fluticasone propionate pMDI. This 
was followed by a 2-week follow-up period. 
During both treatment periods, patients received four 
actuations of fluticasone propionate 250/~g administered 
via a pMDI in the morning and evening. With the exception 
of fl2-agonist therapy, all other concurrent asthma medica- 
tions, including oral steroids (<10 mg day-  l), were per- 
mitted providing that the dose remained constant 
throughout the study. Large volume spacer devices 
(Volumatic TM) were provided if required. Patients attended 
the clinic on seven occasions: at the start and end of the 
run-in period, after week 3 and 6 of each treatment period, 
and at the end of the 2-week follow-up period. 
PATIENTS 
The study recruited patients from 12 hospital centres in the 
U.K. All patients had a documented clinical history of 
severe reversible airways obstruction requiring and re- 
sponding to high doses of inhaled corticosteroids and fl2- 
agonist therapy. The patients were treated on an out- 
patient basis and were eligible for inclusion in the study if 
they were aged > 16 years and required 2--4 mg day - l  of 
inhaled beclomethasone dipropionate or budesonide, or <1 
mg day-  i of inhaled fluticasone propionate. Patients were 
excluded if, in the 4 weeks preceding the study, they had 
changed their regular asthma medication, required anti- 
biotics, been hospitalized for respiratory disease or received 
oral corticosteroids at a dose of > 10 mg day-  l on any one 
day. Current cigarette smokers, patients who had smoked 
cigarettes within the previous 6months and patients treated 
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with depot corticosteroids in the previous 3 months were 
also ineligible. 
In addition, at the end of the run-in period, patients had 
to demonstrate a forced expiratory volume in 1 sec (FEV0 
of <90% of the predicted value (6). They also had to show 
'room for improvement', a criterion necessary to help 
establish clinical equivalence (7). Room for improvement 
was defined as a demonstrable reversibility of peak 
expiratory flow (PEF) or FEVI of >15% and a requirement 
for rescue salbutamol on at least four of the last 7 days of 
the run-in period. The >15% reversibility of lung function 
could have been historically documented within the 
previous 6 months or demonstrated at the beginning of 
the study after inhalation of salbutamol 400/ag. 
The study was approved by the appropriate local ethics 
committee for each centre, and all subjects gave written 
informed consent before entering the study. 
DAILY RECORD CARDS 
Patients were given a mini-Wright peak flow meter and 
daily record cards. Patients were asked to record the 
following information in the diary card each day during the 
run-in and treatment periods: the highest of three PEF 
readings in the morning and evening before taking the 
study medication and preferably after withholding salbu- 
tamol for 4 h; daytime symptom scores measured on a six- 
point scale (0 =no symptoms; 5= symptoms o severe that 
normal daily activities could not be performed); night-time 
symptoms on a five-point scale (0=no symptoms; 
4= symptoms o severe that the patient could not sleep); 
and use of as-required salbutamol. 
CLINIC LUNG FUNCTION 
At each clinic visit, the best of three PEF and FEV~ 
measurements were recorded. PEF was measured using the 
peak flow meter issued to the patient at the start of the run- 
in period. In order to investigate paradoxical broncho- 
spasm, which occurs with pressurized CFC inhalers, (8,9) a 
second PEF measurement was recorded 5 min after taking 
the first dose of inhaled corticosteroid medication in each 
treatment period. 
SAFETY EVALUATION 
Venous blood and urine samples were collected at the start 
and end of the run-in period and at the end of each 6-week 
treatment period for standard haematological nd bio- 
chemical analysis. Blood samples were collected from fasted 
patients between 08-00 and i0-00 hours. Serum samples 
were also analysed for cortisol concentrations and urine 
samples, collected for up to 12h before the same clinic 
visits, were analysed for urinary free cortisol excretion. 
Compliance with this procedure was not assessed. Repeat 
blood or urine samples were collected at the follow-up visit 
if any initial abnormality was detected. All samples were 
analysed by West Middlesex Laboratory, Isleworth, 
Middlesex, U.K. 
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At the start of the run-in and after each 6-week treatment 
period, the investigators conducted a standard physical 
examination of each patient and assessed vital signs (heart 
rate and blood pressure). Once treatment had commenced, 
the oropharynx was examined at each visit to check for the 
visible presence of Candida albicans and dysphonia. The 
severity of dysphonia was rated by the patient as follows: 
1 =absent, 2=mild, 3 =moderate, 4=severe, 5 =very 
severe. 
STAT IST ICAL  ANALYS IS  
The analysis was performed on both the intent-to-treat 
population and on a predefined efficacy population, in line 
with current best practice for equivalence studies (10). 
Equivalence between formulations was established if the 
90% confidence intervals (CI) for the treatment difference 
of mean morning PEF were within + 15 I min- i .  Based on 
a residual standard eviation for PEF of <45 I min-t ,  150 
evaluable patients were required to ensure a power of 80%. 
For both treatment periods, the first 2 weeks were 
disregarded to account for the lack of any formal washout 
period. Although only those patients who provided ata for 
both treatment periods were included in the statistical 
analysis, all the data were summarized. 
Each variable was compared between treatments during 
weeks 3-6 and at week 6. Morning and evening PEF 
(recorded in diary cards) and clinic visit FEVI and PEF 
were analysed using an analysis of variance (ANOVA) 
model for two-way cross-over designs without baselines 
(11). The terms in the model were patient, period and 
treatment. After log-transformation, serum cortisol data 
TABLE 1. Demographic characteristics of the patients 
were also analysed using ANOVA. Urinary cortisol data 
were log-transformed and summarized. 
Symptom scores, additional brochodilator medication 
and dysphonia severity scores were analysed using the 
method of Koch proposed for a cross-over design and the 
Wilcoxon rank sum test (12). 
Results 
One hundred and nineteen patients were randomized to 
receive study treatment, 60 received the fluticasone propio- 
nate HFA 134a pMDI followed by the CFC pMDI and 59 
received the alternative treatment sequence. Table I 
presents baseline demographics for each sequence group. 
Twenty patients were withdrawn from the study after 
randomization, 11were receiving the HFA 134a pMDI and 
nine the CFC pMDI. Reasons for withdrawal included: 
adverse vents (six and five patients, respectively, receiving 
the HFA 134a and CFC pMDI); failure to return (five and 
three patients); unspecified (one patient receiving the CFC 
pMDI). 
DA ILY  RECORD CARD DATA 
During the run-in period there was evidence of a baseline 
difference between the treatment sequence groups. Patients 
who received the HFA 134a pMDI during the first 
treatment period had higher mean values for morning and 
evening PEF at baseline (i.e. pretreatment) han those 
patients who received the CFC pMDI (Table 2). The 
FP FP Total 
HFA 134a---+CFC pMDI CFC---~HFA 134a pMDI 
No. of patients 60 59 119 
Male (%) 27 (45%) 24 (41%) 51 (43%) 
Female (%) 33 (55%) 35 (59%) 68 (57%) 
Age (years) 
Mean 48 50 49 
Range 18-71 18-78 18-78 
Volumatic TM spacer (no. of pts) 
Yes 48 (80%) 44 (75%) 92 (77%) 
No 12 (20%) 15 (25%) 27 (23%) 
Baseline FEVI (1) [mean _ so] 1-95 4- 0.9 1 "69 ___ 0"75 1.82 ___ 0-83 
Medication continued into the study 
(no. of pts): 
Oral steroids 6 (10%) 6 (10%) 12 (10%) 
Methylxanthines 20 (33%) 9 (15%) 29 (24%) 
Anticholinergics 14 (23%) 11 (19%) 25 (21%) 
Sodium cromoglycate 1 (2%) 1 (2%) 2 (2%) 
CFC, chlorofluorocarbons; HFA, hydrofluoroalkane; FEV I forced expiratory volume in 1 sec; FP, fluticasone propionate; 
pMDI, pressurized metered ose inhaler; so, standard eviation. 
TABLE 2. Diary card morning peak expiratory flow (1 min- l )  
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Mean morning PEF ." FP 
(I min- I )  HFA 134a~CFC pMDI 
FP 
CFC-+HFA 134a pMDI 
HFA 134a CFC pMDI CFC pMDI HFA 134a 
pMDI pMDI.  
Baseline + SD (n) 
n*  
Mean t_  SE 
weeks 3-6 
week 6 
334+97 297-1- 102 
60 58 
355-1- 13 360___ 13 325+4 333-t-13 
357___ 14 366-1- 14 328-t- 14 336-t- 13 
*Number of patients who provided ata. 
tAnalysis based on patients who completed both treatment periods. 
CFC, chlorofluorocarbons; FP, fluticasone propionate; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler; 
sE, standard error; sD, standard eviation. 
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FtG. 1. Mean morning peak expiratory flow (PEF) for patients treated with fluticasone propionate (FP) 2 mg day- I  via a 
hydrofluoroalkane (HFA) 134a pressurized metered ose inhaler (pMDI) followed by FP 2 mg day- l  via a chlorottuoro- 
carbon (CFC) pMDI or the same dose of FP via a CFC pMDI followed by an HFA 134a pMDI at (a) week 6 and (b) weeks 
3-6. 
imbalance was also evident in other diary card variables 
and clinic FEVt. 
Mean morning PEF improved throughout he 6-week 
treatment period in all patients. In the HFA 134a~CFC 
pMDI sequence group, morning PEF at baseline was 334 1 
rain-I  and mean value at weeks 3-6 during the HFA; 13~a 
pMDI treatment period was 355 1 min - t .  In the 
CFC~HFA 134a pMDI sequence group, baseline PEF 
was 297 I min-  i and mean morning PEF during weeks 3-6 
of the HFA 134a pMDI treatment period was 333 I min-1 
(Table 2; Fig. I). 
Combined analysis of the data from both sequence 
groups showed that the differences between treatments 
(HFA 134a-CFC pMDI) for mean adjusted morning PEF 
were 2 and 0 1 min-  i, respectively, atweeks 3-6 arid week 6. 
The 90% CI for the differences were within the 16redefined 
-t-15 1 min- i  criterion set for equivalence (weeks 3-6: :---3, 
61 min- l ;  week 6:-.7, 61min-I).  Data for evening PEF 
showed statistical equivalence between the two treatment 
groups, although the clinical improvements were small 
(Table 3). 
There was no significant difference between the two 
treatment groups with respect to the other diary card 
parameters, including daytime and night-time symptom 
scores and use of additional salbutamol (Table 4). Large 
volume spacer devices were used by 77% of the total 
population and their use was not  associated with any 
difference in diary card parameters. 
CL IN IC  LUNG FUNCTION 
Mean FEVI at baseline was 1-821 for all patients. Mean 
FEVI (_+SE) increased to 1.97+0.021 (n=106) and 
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TABLE 3. Diary card evening peak expiratory flow (I min-~) based on overall treatment groups 
Mean evening PEF (1 min- l )  FP FP 
HFA 134a CFC pMDI 
pMDI 
Treatment 90% CI 
difference (_+ SE) 
Baseline +__so 356+92 321 +99 
(n)* (60) (58) 
Adjusted t mean + SE 
over weeks 3-6 356___ 2 353 +2 
(n) (106) (106) 
at week 6 358 + 2 357 + 2 
(n) (97) (97) 
4+2 0, 7 
1+3 -5 ,6  
*Number of patients who provided ata. 
tAdjusted for treatment, period and patient; data presented for all patients. 
CFC, chlorofluorocarbon; CI, confidence interval; FP, fluticasone propionate; HFA, hydrofluoroalkane; pMDI, pressurized 
metered ose inhaler; PEF, peak expiratory flow; SD, standard eviation; SE, standard error. 
TABLE 4. Symptom scores and use of additional inhaled bronchodilator (based on overall treatment groups) 
Baseline* FP FP 
HFA 134a CFC pMDI 
pMDI 
Symptom scores 
Number of patients who provided ata 117 105 105 
Median % days with symptom score <2 100 89 88 
Median %o symptom-free nights 93 89 86 
Median daytime symptom score I 0 1 
Median night-time symptom score 0 0 0 
Additional bronchodilator 
Number of patients who provided ata 118 106 106 
Median %o days with no additional bronchodilator 0 10 4 
Median %o nights with no additional bronchodilator 86 82 82 
Median daytime additional bronchodilator (puffs day-t)  2 2 2 
Median night-time additional bronchodilator (puffs day-1) 0 0 0 
*Overall mean of baseline data for both sequence groups. 
CFC, chlorofluorocarbon; FP, fluticasone propionate; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
2-02+0.021 (n = 102), respectively, after 3 and 6 weeks of 
treatment with the HFA 134a pMDI. In the CFC pMDI 
group, the respective values were 2.00+0-021 (n = 106) and 
1.98+0.021 (n = 102). The treatment differences between 
the two groups (HFA 134a-CFC pMDI) for adjusted mean 
FEV, were -0.021 (90% CI: -0-07, 0-031) during weeks 
3-6 and 0"041 (90% CI: -0.01, 0.081) at week 6. 
Mean baseline clinic visit PEF was 3381 min- l  for all 
patients. During treatment with the HFA 134a pMDI, 
mean clinic visit PEF (+SE) was 366__+41min - l  after 3 
weeks (n = 103) and 369+__3 1min- i  after 6 weeks (n = 100). 
For the CFC pMDI, the respective values were 
365_+41min - I  (n=103) and 369+31min -1 (n=100). 
The treatment differences between the two groups (HFA 
134a-CFC pMDI) for adjusted mean clinic PEF were 
21min - I  (90% CI: -8 ,  11 lmin - I )  over weeks 3-6 and 
01 min - l  (90% CI: -8 ,  7 1 min -1) at week 6. 
HRST-DOSE EFFECT 
The frequency distribution of the percentage change in PEF 
from baseline 5min after administration f the first dose of 
study medication was comparable in the HFA 134a and 
CFC pMDI groups (Fig. 2). A clinically relevant reduction 
in PEF was considered to be greater than 20% of baseline. 
60 
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Fro. 2. Frequency distribution of the percentage change in peak expiratory flow (PEF) 5 min post-inhalation of fluticasone 
propionate (FP) medication either via a hydrofluroalkane (HFA 134a) pressurized metered ose inhaler (pMDI) or via a 
chlorofluorocarbon (CFC) pMDI. 
TABLE 5. Most common (incidence _>10%) and predictable adverse ev nts 
FP FP 
HFA134a pMDI CFC pMDI 
114 ll5 Total number of patients who received treatment 
Number of patients reporting an adverse vent 
Asthma and related events 
Headache 
Upper respiratory tract infection 
Respiratory infection 
Sore throat 
Predictable adverse vents 
Hoarseness 
Candidiasis: mouth 
Rash/skin eruption 
Allergic skin reactions 
88 (77%) 86 (75%) 
23 (20%) 24 (21%) 
18 (16%) 14 (12%) 
18 (16%) 1200%) 
13 (11%) 19 (17%) 
11 (10%) 7 (6%) 
17 (15%) 7 (6%) 
4 (4%) 11 (10%) 
1 (< 1%) 4 (3%) 
1 (< 1%) 0 
CFC, chlorofluorocarbon; FP, fluticasone propionate; HFA, hydrofluoroalkand; pMDI, pressurized metered ose inhaler 
One patient was reported with a reduction in PEF of this 
magnitude but there were no reports of paradoxical 
bronchoconstriction r adverse events immediately after 
dosing. 
SAFETY 
A comparable number of patients in the HFA 134a and 
CFC pMDI groups reported adverse events: 88 patients 
(77%) receiving fluticasone,propionate via the HFA 134a 
pMDI and 86 patients (75%) receiving fluticasone propio- 
Hate via the CFC pMDI. The most commonly reported 
adverse vents during treatment, experienced by >_10% of 
patients in each group, are presented in Table 5 together 
with the incidence of commonly occuring adverse events 
typically associated with inhaled corticosteroids. 
Of the predictable adverse vents, hoarseness was more 
common in the HFA 134a than in the CFC pMDI group 
(17 vs .  seven reports; P=0.032), but conversely, the 
incidence of oral candidiasis was greater in the CFC pMDI 
group (11 vs .  four reports; P=0.106), although not 
statistically significant. The incidence of dysphonia was 
comparable in both groups at week 3 (11 vs .  12% in the 
HFA 134a and CFC pMDI group, respectively) and 
although igher in the HFA 134a pMDI group at week 6 
this was not statistically significantly different (7% differ- 
ence; 90% CI: -2 ,  15). 
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TABLE 6. Serum and urinary cortisol measurements 
All 
Patients 
FP FP. Adjusted* 
HFA 134a CFC pMDI geometric ratio* 
pMDI (90% CI) 
Serum cortisol (mnol I- i) 
Baseline 
geometric mean (CV) 227 (0.56) 
(n) 107 
After 6 weeks* 
geometric mean (CV) 
(n) 
Adjusted geometric mean* (CV) 
07) 
Urinary cortisol (nmol - t) 
Baseline 
geometric mean (CV) 5.36 (1.16) 
(n) (109) 
After 6 weeks* 
geometric mean (CV) 
(n) 
250 (0.61) 213 (0.66) 
(93) (97) 
259 (0.42) 227 (0.42) 
(83) (83) 
6-05 (2.01) 6.14 (2.75) 
(99) (94) 
I. 14 (1.03-1 "27) 2 
*Adjusted for patient, period, treatment. 
*Ratio of mean HFA 134a pMDI to CFC pMDI value. 
~Patients with data for that week in both periods. 
~P = 0.035. 
CFC, chlorofluorocarbon; CI, confidence interval; CV, coefficient of variation; FP, fluticasone propionate; HFA, 
hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
Mean serum cortisol evels were higher after treatment 
with fluticasone propionate administered via the HFA 134a 
pMDI than via the CFC pMDI (ratio of geometric means: 
1.14; P=0.035) (Table 6). This difference reflected an 
increase in mean serum cortisol from baseline with the 
HFA 134a formulation compared with no change or a 
slight reduction with the CFC formulation. Therefore, there 
was no evidence of cortisol suppression with the HFA 134a 
product. The distribution of individual serum cortisol 
values was also similar with both treatments. In all, two 
patients on either treatment had values below the normal 
range. In contrast, urinary cortisol levels were raised 
compared with baseline on both treatments and were 
comparable in the two groups (Table 6). 
Discuss ion  
These findings demonstrate hat the efficacy and tolerability 
of FP 2mgday - j  in patients with severe asthma is 
comparable whether administered via an HFA 134a or 
CFC pMDI providing 250 #g of drug per actuation. As 
shown previously, these two products are similar with 
respect o particle size distribution and fine particle mass 
(13) and the present study provides clinical evidence that 
the two products behave similarly in vivo. These results also 
concur with those of other published studies investigating 
HFA 134a; when used to replace the CFC propellants 11 
and 12 in salbutamol pMDIs and fluticasone propionate 
pMDIs of various trengths, HFA 134a did not compromise 
the efficacy or tolerability of either therapeutic agent (14--17). 
The degree of asthma severity in the patients enrolled in 
this study precluded the use of a formal washout period. In 
an effort to overcome this, data from the first 2 weeks of 
each treatment period were not used in the analyses. 
Furthermore, patients had to demonstrate 'room for 
improvement' (based on their ability to demonstrate a 
>_15% reversibility to salbutamol 400#g) to minimize the 
risk of dosing at the top of the dose-response curve (7). 
There were differences between the patients in the two 
sequence groups at baseline; by chance, patients rando- 
mized to the HFA 134a pMDI in the first 6-week treatment 
period had higher baseline values for all parameters than 
those patients randomized to initial treatment with the 
CFC pMDI. Nonetheless, there was a trend towards a 
similar improvement in the efficacy parameters, in both 
groups compared to baseline. 
The present study was powered (>_80%) to show clinical 
equivalence. This was defined by the 90% CI for the 
treatment difference in the primary efficacy parameter, 
mean morning PEF, using limits of _ 15 I min-  l, if at least 
150 evaluable patients were enrolled in this study. The 
lower number of patients recruited was, however, balanced 
by the smaller esidual standard eviation so the power of 
the study was increased from that planned. This was 
supported by a more restrictive analysis (based on 95% 
CIs) which demonstrated quivalence at the specified level 
(+ 15 1 min- i) .  In this study, the increases in mean morning 
PEF from baseline at the end of treatment were similar to 
that reported in another study evaluating fluticasone 
propionate 2mg day -) for 6 weeks (24 I min - l )  (18) and 
smaller than that reported in a longer 16-week study using 
the same dose of fluticasone propionate (83 1 rain - I )  (5). 
Inhaled corticosteroids are well tolerated but the like- 
lihood of systemic side-effects tends to increase as the 
dosage is increased, particularly hypothalamic pituitary 
adrenal (HPA) axis suppression (19). The safety profile of 
fluticasone propionate in this respect is good, having low 
systemic absorption after oral administration (20) and 
being as effective at half the dose of other currently used 
inhaled corticosteroids (21). In this study, fluticasone 
propionate administered via an HFA 134a pMDI resulted 
in a modest increase in serum cortisol levels at the end of 
the 6-week treatment period but this was neither of clinical 
or statistical significance. In previous tudies, mean serum 
cortisol levels remained within the normal range during 
treatment with a wide range of fluticasone propionate 
dosages (21,22), although small decreases have been 
observed in two studies (5,18). 
Safety monitoring showed that both formulations of 
fluticasone propionate were well tolerated and associated 
with a similar incidence of adverse events. The incidence 
and type of adverse events was not unexpected in a 
population of patients with severe asthma receiving high- 
dose inhaled corticosteroid therapy. During the analysis of 
adverse events, only the incidence of hoarseness differed 
significantly between the two groups. This result may have 
been due to the fact that multiple tests were performed on 
the same subjects, although a true effect cannot be ruled 
out. 
In conclusion, the results of this study demonstrate hat 
at a microgram equivalent dose the efficacy and tolerability 
of fluticasone propionate when propelled by a non-CFC 
propellant, HFA 134, are comparable with those of 
fluticasone propionate propelled by the CFC propellants 
11 and 12. 
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